Recent Pfizer Press Releases

  • 8/27/07 7:30 am EDT

    Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds

    NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) (“companies”) today announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007. Pfizer’s DGAT-1 discovery program includes advanced pre-clinical compounds with potential applications for themore...
  • 8/22/07 9:00 am EDT

    Brings Extensive Operating and Financial Experience in Global Companies Undergoing Rapid Change

    NEW YORK--(BUSINESS WIRE)--Pfizer today announced that Frank A. D’Amelio, a senior executive with almost three decades of extensive operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as both chief operating officer and chief financial officer at Lucent, will become Pfizer’s Senior Vice President and Chief Financial Officer effective in mid-September. Mr. D’Amelio, who ismore...
  • 8/6/07 1:00 pm EDT

    First in a New Class of Oral HIV Medicines in More Than a Decade

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved SelzentryTM (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. “There is a profound need for newmore...
  • 8/2/07 7:01 pm EDT
    PARIS--(BUSINESS WIRE)--Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published today in the Annals of Oncology (http://annonc.oxfordjournals.org), confirm the value of switching from tamoxifen to an aromatase inhibitor (AI), such as exemestane, for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.i Approximately 360,000 women inmore...
  • 7/30/07 12:01 pm EDT

    In Time for the August Travel Rush, CereniaTM (maropitant citrate) Helps Dogs Come Along for the Ride

    NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health, a business of Pfizer Inc (NYSE: PFE), announced today that Cerenia™ (maropitant citrate), the first and only FDA-approved medication for the prevention and treatment of canine vomiting from a wide range of causes, including motion sickness, is now available by prescription in the United States. Vomiting is one of the most common reasons owners take their dogs to the veterinarian. Accordingmore...
  • 7/25/07 7:04 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Spanish court has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor. The Commercial Court of First Instance Number 4 in Barcelona, which issued the ruling, found a second patent covering a stabilized formulation that includes atorvastatin is invalid. The patents were challenged by generic manufacturer Ranbaxy.more...
  • 7/25/07 12:01 am EDT
    NEW YORK--(BUSINESS WIRE)--Rates of virologic suppression in patients receiving Pfizer’s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6% vs. 73.1% for <400 copies/ml and 65.3% vs. 69.3% at <50 copies/ml in the full analysis set (FAS) study population (n= 360, maraviroc/ n= 361, efavirenz), according to a late breaker presentation at the International AIDS Society conference in Sydney, Australia. Increases inmore...
  • 7/19/07 5:26 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending marketing authorization for Celsentri® (maraviroc), the first CCR5 antagonist for use in combination with other antiretroviral agents for treatment-experienced adult patients where only CCR5-tropic virus is detectable. The CHMP’s positivemore...
  • 7/18/07 2:34 pm EDT

    Fabrus LLC to Develop New Antibody Technologies in Search For New Medicines

    NEW YORK--(BUSINESS WIRE)-- Pfizer today announced its first occupant for the company’s Incubator – a new development where scientific entrepreneurs progress their ideas towards innovative treatments for serious diseases. Vaughn Smider MD, PhD, an assistant professor at The Scripps Research Institute, in La Jolla CA, will work to develop a unique technology to identify antibodies that might lead to new therapies. He willmore...
  • 7/18/07 6:45 am EDT
    • Second Quarter 2007 was Impacted by Loss of Exclusivity for Zoloft and Norvasc, Timing of Expenses and Lipitor Performance in the U.S.; New Products Chantix, Sutent, Lyrica are Performing Extremely Well
    • Company Makes Significant Progress Against Priorities Announced in January 2007, including Creating a Lower, More Flexible Cost Base
    • Company Developing Longer-Range Plans for a Rapidly Changing Healthcare Marketplace
    NEW YORK--(BUSINESS WIRE)--Pfizer: ($ millions, except per-share amounts)           Second Quarter   Year to Date     2007  more...